Results 41 to 50 of about 70,073 (274)

Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer

SAGE Open Medicine, 2023
Objectives: To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer.
Gen Kawaguchi, Kohei Akazawa, Taro Ikeda, Yohei Ikeda, Noboru Hara, Tsutomu Nishiyama   +5 more
doaj   +1 more source

Visceral Disease in Castration-resistant Prostate Cancer [PDF]

European Urology, 2014
Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359 CRPC patients treated between June 2003 and December 2011, the frequency of radiologically detected visceral metastases before death was 32%.
Pezaro C. J., Omlin A., Lorente D., Nava Rodrigues D., Ferraldeschi R., Bianchini D., Mukherji D., Riisnaes R., Altavilla A., Crespo M., Tunariu N., De Bono J. S., Attard G.   +12 more
openaire   +3 more sources

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.

New England Journal of Medicine, 2020
BACKGROUND Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking
C. Sternberg, K. Fizazi, F. Saad, N. Shore, U. de Giorgi, D. Penson, U. Ferreira, E. Efstathiou, K. Madziarska, M. Kolinsky, D. Cubero, B. Noerby, F. Zohren, Xun Lin, K. Modelska, J. Sugg, J. Steinberg, M. Hussain   +17 more
semanticscholar   +1 more source

Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. [PDF]

PLoS ONE, 2012
The recently described transcriptomic switch to a mitosis program in castration-resistant prostate cancer (CRPC) suggests that mitotic proteins may be rationally targeted at this lethal stage of the disease.
Kanishka Sircar, Heng Huang, Limei Hu, Yuexin Liu, Jasreman Dhillon, David Cogdell, Armen Aprikian, Eleni Efstathiou, Nora Navone, Patricia Troncoso, Wei Zhang   +10 more
doaj   +1 more source

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy

Frontiers in Oncology, 2016
Historically, androgen-deprivation therapy was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer, there are a few life-prolonging drugs, including taxanes such as docetaxel
Masaki eShiota, Akira eYokomizo, Masatoshi eEto   +2 more
doaj   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators

Asian Journal of Andrology, 2023
Prostate cancer is one of the most common diseases in men worldwide. Surgery, radiation therapy, and hormonal therapy are effective treatments for early-stage prostate cancer. However, the development of castration-resistant prostate cancer has increased
Sayuri Takahashi, Ichiro Takada
doaj   +1 more source

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

New England Journal of Medicine, 2020
BACKGROUND Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer.
K. Fizazi, N. Shore, T. Tammela, A. Ulys, E. Vjaters, S. Polyakov, M. Jievaltas, M. Luz, B. Alekseev, I. Kuss, M. Le Berre, O. Petrenciuc, A. Snapir, T. Sarapohja, Matthew R. Smith   +14 more
semanticscholar   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. [PDF]

PLoS ONE, 2012
MicroRNAs (miRs) are small, endogenous, non-coding RNAs that regulate the stability and/or translation of complementary mRNA targets. MiRs have emerged not only as critical modulators of normal physiologic processes, but their deregulation may ...
Reema A Ishteiwy, Toby M Ward, Derek M Dykxhoorn, Kerry L Burnstein   +3 more
doaj   +1 more source